Skip to main content
SpringerLink
Log in

New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) is a major public health issue because infection may lead to liver failure, cirrhosis and hepatocellular carcinoma. In patients with renal dysfunction, hepatitis C can also worsen the underlying renal disease. Treating HCV infection is thus mandatory in this population. New therapies for hepatitis C have recently been developed, and some have been launched. Most of them are used in combination with the current standard of care, ribavirin and pegylated interferon alfa. Some of them can be used in regimens without ribavirin and/or pegylated interferon. However, few data are available on dosage adjustment for renal function in patients receiving these very new drugs. We reviewed the literature on this subject and gathered information, although scarce, to propose guidelines for using these drugs in patients with chronic kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kamar N, Alric L, Izopet J, Rostaing L. Hepatitis C virus and kidney disease. Clin Res Hepatol Gastroenterol. 2013;37:328–33.

    Article  PubMed  Google Scholar 

  2. Vallet-Pichard A, Pol S. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol. 2013;37:340–6.

    Article  PubMed  Google Scholar 

  3. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14:3270–7.

    Article  PubMed  Google Scholar 

  4. Brennan BJ, Wang K, Blotner S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57:6097–105.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Tseng P-L, Chen T-C, Chien Y-S, et al. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis. 2013;62:789–95.

    Article  CAS  PubMed  Google Scholar 

  6. Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669–89 (quiz 690).

    Article  CAS  PubMed  Google Scholar 

  7. Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol Adv Appl. 2014;6:1–17.

    Google Scholar 

  8. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail. Hepatology. 2011;54:3–5.

    Article  PubMed  Google Scholar 

  9. Van Heeswijk R. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir. Available at http://download.journals.elsevierhealth.com/pdfs/journals/0168-8278/PIIS0168827811612476.pdf. Accessed 25 Feb 2014.

  10. Garg V, Kauffman RS, Beaumont M, van Heeswijk RPG. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17:1211–21.

    Article  CAS  PubMed  Google Scholar 

  11. Dumortier J, Guillaud O, Gagnieu M-C, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56:146–9.

    Article  CAS  PubMed  Google Scholar 

  12. Basu PP, Siriki R, Shah NJ, et al. Telaprevir with adjusted dose of ribavirin in naïve CHC-G1: efficacy and treatment in CHC in hemodialysis population. In: TARGET C (RCT) 48th annual meeting of the european association for the study of the liver, April 24–28, 2013. Amsterdam, Netherlands; 2013. Abstract 67.

  13. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20–7.

    Article  CAS  PubMed  Google Scholar 

  14. Treitel M, Marbury T, Preston RA, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51:619–28.

    Article  CAS  PubMed  Google Scholar 

  15. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology. 2014;59:46–8.

    Article  CAS  PubMed  Google Scholar 

  16. Loustaud-Ratti V, Carrier P, Vong C, Essig M. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014;59(6):2426.

  17. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int. 2013;33(Suppl 1):80–4.

    Article  CAS  PubMed  Google Scholar 

  19. Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2014. doi:10.3851/IMP2773.

  20. Garimella T, He B, Luo W-L, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. In: 64th annual meeting of the american association for the study of liver diseases Nov 1–5, 2013. Washington, DC; 2013. Abstract.

  21. Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. In: 47th annual meeting of the european association for the study of the liver (EASL), April 18–22, 2012. Barcelona, Spain; 2012. Abstract 1101.

  22. Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Invest Drugs. 2013;22:527–36.

    Article  CAS  Google Scholar 

  23. Clinical trials.gov. Sofosbuvir plus ribavirin in subjects with HCV infection and renal insufficiency. Available at http://clinicaltrials.gov/ct2/show/NCT01958281. Accessed 28 Feb 2014.

  24. Clinical trials.gov. Pharmacokinetic and safety study of daclatasvir in patients with renal impairment. Available at http://clinicaltrials.gov/ct2/show/NCT01830205?term=daclatasvir+and+kidney&rank=1. Accessed 28 Feb 2014.

  25. Garimella T, Wang R, Luo W-L, et al. The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, 19–21 May 2014. Available at http://www.natap.org/2014/Pharm/Pharm_18.htm. Accessed 10 July 2014.

  26. Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Invest Drugs. 2014;23:561–71.

    Article  CAS  Google Scholar 

  27. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.

    Article  CAS  PubMed  Google Scholar 

  28. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.

    Article  PubMed  Google Scholar 

  29. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Service ICAR is funded by unrestricted educational grants from Gilead, Roche, Daiichi Sankyo, Vifor Pharma, Ipsen and Teva. Sarah Zimner-Rapuch has received no funding that is relevant to the content of this article. Nicolas Janus has received consulting fees from Roche and Fresenius Medical Care. Gilbert Deray has received an honorarium from Gilead. Vincent Launay-Vacher has received consulting fees from Gilead, Vifor, Roche, Sanofi and Pfizer. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Service ICAR, Service de Néphrologie, Groupe Hospitalier Pitié-Salpêtrière, 47–83 Boulevard de l’Hôpital, 75013, Paris, France

    Sarah Zimner-Rapuch, Nicolas Janus & Vincent Launay-Vacher

  2. Service de Néphrologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

    Gilbert Deray

Authors
  1. Sarah Zimner-Rapuch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Janus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilbert Deray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincent Launay-Vacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Zimner-Rapuch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zimner-Rapuch, S., Janus, N., Deray, G. et al. New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment. Drugs 74, 1307–1313 (2014). https://doi.org/10.1007/s40265-014-0268-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0268-7

Keywords

Search

Navigation